Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s40291-022-00594-2.pdf
Reference40 articles.
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. SEER. Cancer stat facts: prostate cancer April 2021. 2021. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 30 Mar 2022.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): prostate cancer. Version 3.2022—January 10 2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 30 Mar 2022.
4. Heidegger I, Kesch C, Kretschmer A, et al. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Ther Adv Med Oncol. 2022. https://doi.org/10.1177/17588359221081922.
5. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–61.
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study;BMC Cancer;2024-01-29
2. Novel treatment strategies to overcome resistance in prostate cancer;Therapy Resistance in Prostate Cancer;2024
3. Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical 177Lu-DOTA-PSMA;Bulletin of Experimental Biology and Medicine;2023-12
4. Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry;Expert Opinion on Biological Therapy;2023-11-02
5. A Perspective of the Amide Group Containing FDA Approved Anticancer Drugs from 2021–2022 (A Review);Russian Journal of Bioorganic Chemistry;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3